Patents Assigned to Hadasit Medical Research Services and Development Ltd.
-
Patent number: 11801220Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).Type: GrantFiled: November 8, 2018Date of Patent: October 31, 2023Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
-
Patent number: 11746324Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.Type: GrantFiled: December 10, 2021Date of Patent: September 5, 2023Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Benjamin Eithan Reubinoff, Orna Singer
-
Patent number: 11718666Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.Type: GrantFiled: July 29, 2021Date of Patent: August 8, 2023Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventor: Rifaat Safadi
-
Publication number: 20230157896Abstract: The present invention relates to a device for repair of a region within an ear via a natural orifice, the device comprising a body. The body comprises a first port for visibly identifying the region to be sealed, the region being inside the ear; and a second port through which a seal can be introduced into the ear through the device. The region comprises a perforation of a tympanic membrane of the ear and the device is a speculum. The present invention also relates to method for repairing a perforation in a tympanic membrane using the same device.Type: ApplicationFiled: March 11, 2021Publication date: May 25, 2023Applicants: National University of Singapore, Hadasit Medical Research Services And Development Ltd, Yissum Research Development Company of the Hebrew University of Jerusalem LtdInventors: Menachem Gross, Shlomo Magdassi, Yin Chiang Boey, Ngeow Khing Chia
-
Publication number: 20230078665Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.Type: ApplicationFiled: November 10, 2022Publication date: March 16, 2023Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
-
Patent number: 11583537Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising use of artemisone in combination with at least one antiviral compound selected from maribavir, cidofovir, brincidofovir, valganciclovir, and letermovir, and the combination provides a synergistic anti-viral effect. The invention also provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisone in combination with ganciclovir, wherein the molar ratio between artemisone and ganciclovir is about 1:100 to 100:1, and the combination provides a synergistic anti-viral effect. Pharmaceutical compositions comprising artemisone and at least one of said antiviral compounds are provided as well.Type: GrantFiled: September 21, 2020Date of Patent: February 21, 2023Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventor: Dana Wolf
-
Patent number: 11565091Abstract: A method for influencing cerebral perfusion in a patient by modifying a volume of a volume adaptor introduced into a cerebral ventricle of the patient, the method comprising identifying a timing of a cerebral blood inflow and/or outflow in a cardiac activity of the patient, modifying a volume of the volume adaptor in synchronization to the identified timing of the cerebral blood flow, to an amount sufficient to modify an intracranial pressure in the cerebral ventricle, such that a flow of the cerebral blood flow is enhanced. In some exemplary embodiments of the invention, the inflation duration of the volume adapter is short relative to the cardiac cycle.Type: GrantFiled: November 16, 2017Date of Patent: January 31, 2023Assignees: Ramot at Tel-Aviv University Ltd., Tel HaShomer Medical Research Infrastructare and Services Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Ofer Barnea, Omer Doron
-
Patent number: 11530251Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.Type: GrantFiled: May 20, 2019Date of Patent: December 20, 2022Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
-
Patent number: 11478453Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.Type: GrantFiled: July 20, 2017Date of Patent: October 25, 2022Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Iris Lavon Ben Moshe, Tamar Canello Avramovitch
-
Patent number: 11466323Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.Type: GrantFiled: July 13, 2018Date of Patent: October 11, 2022Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Yuval Dor, Ruth Shemer, Benjamin Glaser, Judith Magenheim
-
Publication number: 20220233477Abstract: A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.Type: ApplicationFiled: June 11, 2020Publication date: July 28, 2022Applicant: Hadasit Medical Research Services and Development Ltd.Inventors: Benjamin Eithan REUBINOFF, Etti BEN-SHUSHAN
-
Publication number: 20220225612Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.Type: ApplicationFiled: November 22, 2021Publication date: July 21, 2022Applicants: NOBIO Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Nathan Zaltsman, Ervin Itzhak Weiss, Nurit Beyth
-
Publication number: 20220213445Abstract: A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50% of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.Type: ApplicationFiled: May 22, 2020Publication date: July 7, 2022Applicant: Hadasit Medical Research Services and Development Ltd.Inventors: Benjamin Eithan REUBINOFF, Michal GROPP
-
Publication number: 20220184154Abstract: A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.Type: ApplicationFiled: February 28, 2022Publication date: June 16, 2022Applicants: Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Eran ELINAV, Yotam COHEN, Ahinoam LEV-SAGIE, Debra GOLDMAN-WOHL
-
Patent number: 11298151Abstract: Device for accessing a pericardial space of a subject in need thereof, the device including a tubular member having an atraumatic distal end and a thread formed on, and at least partially around, the outer surface of the tubular member, proximally to the distal end; wherein the thread is configured to cut, puncture and/or penetrate a pericardium.Type: GrantFiled: June 17, 2018Date of Patent: April 12, 2022Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Ran Eliaz, Yonathan Avraham Demma, Ziv Menshes, Or Hazan, Eva Abramov, Yaakov Nahmias, Amnon Buxboim, Yoav Kan-Tor, Yoav Mintz, Elchanan Fried
-
Patent number: 11273201Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.Type: GrantFiled: April 24, 2019Date of Patent: March 15, 2022Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
-
Patent number: 11261433Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.Type: GrantFiled: January 31, 2017Date of Patent: March 1, 2022Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Ithai Waldhorn, Benjamin Eithan Reubinoff
-
Patent number: 11246912Abstract: The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject.Type: GrantFiled: August 30, 2018Date of Patent: February 15, 2022Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventors: Rinat Abramovitch, Esther Goldlist
-
Patent number: 11241147Abstract: A guided tracheal intubation system using an autonomous modulated light source, outputting modulated illumination at a constant level, and externally applied to the subject's larynx region. An optical imaging system receives a video stream from within the subject's throat, including modulated illumination from the subject's trachea. A display control system performs signal processing on the modulated content of the images, and outputs frames of those images in which the intensity level of illumination from the trachea can be controlled without any need to change the illumination output from the modulated light source. The light source has no connection with the rest of the system, and need contain no more than a battery, a power supply circuit and a light source. It can therefore be of low cost and can be made disposable, such as in the form of an adhesive patch applied to the subject's neck.Type: GrantFiled: May 16, 2014Date of Patent: February 8, 2022Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Itai Hayut, Elchanan Fried, Yaakov Nahmias, Tommy Weiss-Sadan, Ariel Shrem
-
Patent number: 11230696Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.Type: GrantFiled: July 28, 2016Date of Patent: January 25, 2022Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Benjamin Eithan Reubinoff, Orna Singer